SG11202000484TA - Cd38 antibody - Google Patents

Cd38 antibody

Info

Publication number
SG11202000484TA
SG11202000484TA SG11202000484TA SG11202000484TA SG11202000484TA SG 11202000484T A SG11202000484T A SG 11202000484TA SG 11202000484T A SG11202000484T A SG 11202000484TA SG 11202000484T A SG11202000484T A SG 11202000484TA SG 11202000484T A SG11202000484T A SG 11202000484TA
Authority
SG
Singapore
Prior art keywords
stevenage
tusk
catalyst
international
therapeutics
Prior art date
Application number
SG11202000484TA
Other languages
English (en)
Inventor
Anne Goubier
Josephine Salimu
Corzo Beatriz Goyenechea
Pascal Merchiers
Kevin Moulder
Nina Eissler
Simone Filosto
Hemanta Baruah
Bianka Prinz
Original Assignee
Black Belt Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Black Belt Therapeutics Ltd filed Critical Black Belt Therapeutics Ltd
Publication of SG11202000484TA publication Critical patent/SG11202000484TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202000484TA 2017-08-16 2018-08-16 Cd38 antibody SG11202000484TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762546336P 2017-08-16 2017-08-16
US201762582609P 2017-11-07 2017-11-07
PCT/EP2018/072272 WO2019034753A1 (en) 2017-08-16 2018-08-16 ANTIBODY CD38

Publications (1)

Publication Number Publication Date
SG11202000484TA true SG11202000484TA (en) 2020-02-27

Family

ID=63259520

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000484TA SG11202000484TA (en) 2017-08-16 2018-08-16 Cd38 antibody

Country Status (9)

Country Link
US (2) US11236173B2 (enExample)
EP (1) EP3668543A1 (enExample)
JP (1) JP7299873B2 (enExample)
KR (1) KR102770110B1 (enExample)
CN (1) CN111032086B (enExample)
AU (1) AU2018316522B2 (enExample)
CA (1) CA3072296A1 (enExample)
SG (1) SG11202000484TA (enExample)
WO (1) WO2019034753A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3126735A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
AU2020239048B2 (en) 2019-03-12 2025-10-16 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
KR20210144821A (ko) 2019-03-29 2021-11-30 아르커스 바이오사이언시즈 인코포레이티드 규명된 아데노신 지문을 이용한 암의 치료방법
WO2021003074A1 (en) * 2019-07-03 2021-01-07 Crystal Bioscience Inc. Anti-cd38 antibody and methods of use thereof
CA3190385A1 (en) 2020-09-10 2022-03-17 Alexander Anthony Zukiwski Methods of blood screening
CN112300281B (zh) * 2020-10-29 2021-06-11 杭州爱唯生命科技有限公司 含有nk细胞的药物组合物及其治疗癌症的用途
CN114437215B (zh) * 2020-11-05 2023-02-07 上海麦济生物技术有限公司 抗人cd38抗体及其制备方法和用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
AU2011202520C1 (en) 2002-10-17 2016-02-18 Genmab A/S Human monoclonal antibodies against CD20
CA2555185C (en) 2004-02-06 2020-03-24 Morphosys Ag Anti-cd38 human antibodies and uses therefor
JP2008504013A (ja) 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト 抗ｃｄ３８ヒト抗体及びその用途
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
EA015584B1 (ru) 2005-03-23 2011-10-31 Генмаб А/С Антитело к cd38 человека и его применение
AR053489A1 (es) 2005-05-24 2007-05-09 Morphosys Ag Generacion perfilado de anticuerpos terapeuticos totalmente derivados de hucal gold humanos especificos para cd38 humano
JP5362359B2 (ja) * 2005-10-12 2013-12-11 モルフォシス アーゲー ヒトＣＤ３８に特異的な完全ヒトＨｕＣＡＬＧＯＬＤ由来の治療抗体の生成とプロファイリング
AU2016228249A1 (en) 2006-09-26 2016-10-06 Genmab A/S Combination treatment of CD38-expressing tumors
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
AU2013209322A1 (en) 2006-10-19 2013-08-15 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer
CN103172743B (zh) 2006-12-01 2015-04-08 梅达雷克斯有限责任公司 结合cd22的人抗体及其用途
CN101605906A (zh) 2006-12-14 2009-12-16 梅达雷克斯公司 结合cd70的人类抗体及其用途
US20100150950A1 (en) 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
NZ720288A (en) 2006-12-27 2020-02-28 Harvard College Compositions and methods for the treatment of infections and tumors
CA2697193C (en) 2007-09-14 2017-06-06 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CA2743361C (en) 2008-10-06 2021-05-25 Neil R. Cashman Methods and systems for predicting misfolded protein epitopes
SG178925A1 (en) 2009-09-22 2012-04-27 Volker Sandig Process for producing molecules containing specialized glycan structures
WO2012009568A2 (en) 2010-07-16 2012-01-19 Adimab, Llc Antibody libraries
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
MX2015012326A (es) 2013-03-15 2016-03-08 Genentech Inc Anticuerpos anti-crth2 y su uso.
EP3954713A3 (en) * 2014-03-28 2022-03-30 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
MA40894A (fr) 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
CN107427566B (zh) 2014-12-01 2021-08-17 宾夕法尼亚大学理事会 Dna抗体构建体及其使用方法
WO2016164656A1 (en) * 2015-04-08 2016-10-13 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd38
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
HUE066300T2 (hu) 2015-06-24 2024-07-28 Janssen Biotech Inc Immunmoduláció és szolid tumorok kezelése CD38-hoz specifikusan kötõdõ antitestekkel
US10358497B2 (en) 2015-09-29 2019-07-23 Amgen Inc. Methods of treating cardiovascular disease with an ASGR inhibitor
KR20180053674A (ko) 2015-10-02 2018-05-23 에프. 호프만-라 로슈 아게 공자극 tnf 수용체에 특이적인 이중특이성 항체
WO2021057978A1 (zh) 2019-09-27 2021-04-01 南京金斯瑞生物科技有限公司 抗vhh域抗体及其用途

Also Published As

Publication number Publication date
CA3072296A1 (en) 2019-02-21
NZ761838A (en) 2025-03-28
KR20200036861A (ko) 2020-04-07
WO2019034753A1 (en) 2019-02-21
AU2018316522B2 (en) 2025-02-20
KR102770110B1 (ko) 2025-02-20
US11236173B2 (en) 2022-02-01
JP7299873B2 (ja) 2023-06-28
AU2018316522A1 (en) 2020-03-05
US12162949B2 (en) 2024-12-10
US20200362050A1 (en) 2020-11-19
CN111032086A (zh) 2020-04-17
US20220135697A1 (en) 2022-05-05
EP3668543A1 (en) 2020-06-24
CN111032086B (zh) 2023-09-26
JP2020533965A (ja) 2020-11-26

Similar Documents

Publication Publication Date Title
SG11202000484TA (en) Cd38 antibody
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11202000321PA (en) Cd38 modulating antibody
SG11201806992VA (en) Antibodies to tigit
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201803956UA (en) Anti-dr5 antibodies and methods of use thereof
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201907848YA (en) Antibodies binding to vista at acidic ph
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201908578YA (en) Fc-optimized anti-cd25 for tumour specific cell depletion
SG11201809064QA (en) Chimeric neurotoxins
SG11201901899PA (en) Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201906961UA (en) Polypeptide variants and uses thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201908326YA (en) Methods of treating neurodegenerative diseases